Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • India's dependence on...

    India's dependence on pharma imports from China: Minister informs parliament

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-17T15:50:54+05:30  |  Updated On 17 March 2020 3:50 PM IST
    Indias dependence on pharma imports from China: Minister informs parliament

    Delhi: Through a written reply in the Lok Sabha Shri. D.V. Sadananda Gowda, Minister for Chemicals & fertilizers informed the parliament about the import of APIs /drugs and the extent of its dependence on China for the same.

    The Indian Pharmaceutical industry is 3rd largest in the world in terms of volume and 14th largest in terms of value. India exported medicines worth US $14389 mn in Financial Year 2018-19. India also exported Bulk Drug/Drug Intermediates worth the US $ 3911mn in Financial Year 2018-19.

    However, the country also imports various Bulk Drugs/Active Pharmaceutical Ingredients (APIs) for producing medicines. Two-thirds of the total imports of Bulk Drugs/ Drug Intermediates is from China. The imports from China are mainly due to economic considerations. The details of India's imports of Bulk Drugs/ Drug Intermediates (including from China) are as under:

    Year

    Total imports

    (US $ mn)

    Imports from China

    (US$ mn)

    Per cent of Imports from China

    2018-19

    3560.35

    2405.42

    67.56%

    As per the information received from the port offices of CDSCO, the quantity of raw materials imported for the formulation of antibiotic medicines in the country during each of the last three years is as follows:

    Year

    Quantity of raw materials imported for the formulation of antibiotic medicines in the country (in MTs)

    2019

    11230.50

    2018

    12006.11

    2017

    5591.44

    The minister added that the Department of Pharmaceuticals has constituted a Committee under the chairmanship of Dr Eshwara Reddy, Joint Drugs Controller, Central Drugs Standard Control Organization (CDSCO) to address the issue of drug security in the country in the context of novel coronavirus outbreak in China.

    Based on the recommendations of the Committee, the department has issued necessary instructions to National Pharmaceutical Pricing Authority (NPPA), Drugs Controller General of India (DCGI) and State Governments to ensure an adequate supply of APIs and formulations at affordable prices in the market and to prevent black-marketing, illegal hoarding, creating artificial shortages in the country.

    In this regard, the Department of Pharmaceuticals has written to DGFT to restrict exports of 13 API and formulations made out of these APIs which includes paracetamol.

    NPPA has also written to Chief Secretaries of States with copies to Principal Secretaries Health and State Drug Controllers requesting them to closely monitor the production and availability of APIs and formulations to prevent the black marketing and hoarding in their States and UTs as well as to ensure that there is no violation of provisions of Drugs (Prices Control) Order, 2013 with regard to compliance of ceiling prices/ permissible increase in prices of scheduled/ non-scheduled formulations respectively.

    Read also: Coronavirus Scare: Minister Apprises Parliament About The Availability Of Drugs And Shortages

    The Department of Pharmaceuticals has formulated a Scheme namely 'Assistance to Bulk Drug Industry for Common Facility Centre' for providing assistance of up to Rs.100 crore for creation of Common Facility Centre (CFC) in any upcoming bulk drug park promoted by State Governments/State Corporations. The department has given 'In-principle' approval to the following proposals under this scheme:

    Govt. of Andhra Pradesh (AP Economic Cities Promotional Corporation Ltd.)

    Govt. of Telangana (Telangana State Industrial Infrastructure Corporation Ltd.)

    Govt. of Himachal Pradesh (HP State Industrial Development Corporation Ltd.)

    As per the said scheme, the time frame for development of a CFC is 2 years from the date of final approval.

    Read also: Following SC Orders, CDSCO Asks Pharma Manfacturers Submit Data On 66 Fixed-Dose Combinations

    active-pharmaceutical-ingredientscdscodepartment-of-pharmaceuticals

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok